NCT07148960
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
Enrolling by Invitation
PHASE4Ages 18+InterventionalTreatmentWest Virginia UniversityInvestigator-initiated
~300 participants
Updated 2025-09-17 on ClinicalTrials.gov
What's tested:Early Dual IV Antibiotic Therapy - MRSAEarly Dual IV Antibiotic Therapy - MSSASingle Agent IV Antibiotic Therapy - MRSASingle Agent IV Antibiotic Therapy - MSSA
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of participants with prolonged bacteremia (≥ 6 days)
Measured over Up to 12 weeks post hospital discharge
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesWest Virginia1
Study leadership
- Joy J Juskowich, MD · PRINCIPAL_INVESTIGATOR · West Virginia University
- Arif R Sawari, MD, MSc, MBA · PRINCIPAL_INVESTIGATOR · West Virginia University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
The patient is hospitalized at J.W. Ruby Memorial Hospital, Berkeley Medical Center, Camden Clark Medical Center, Princeton Community Hospital, Thomas Hospital, United Hospital Center, or Wheeling Hospital
The patient has been identified to have Staphylococcus aureus bacteremia
The patient is able to participate in lab monitoring and in-person or telemedicine ID Clinic follow-up
Exclusion
The patient or an appointed medical decision maker is unable to give informed consent
The patient is a prisoner, pregnant, and/or mentally handicapped
The patient is determined unsafe for enrollment at the primary team's discretion
What this trial measures
- Percentage of participants with prolonged bacteremia (≥ 6 days)Up to 12 weeks post hospital discharge
Percentage of participants with prolonged bacteremia (≥ 6 days) up to 12 weeks post hospital discharge.
- Seeding of a New Site - IncidenceUp to 12 weeks post hospital discharge
Incidence of new infection of heart valve, joint, or spine up to 12 weeks post hospital discharge.
- All-Cause MortalityUp to 12 weeks post hospital discharge
Number of participants who died from any cause up to 12 weeks post hospital discharge.